WuXi AppTec mulls gene unit sale to soften U.S. legal blow
Market talk is swirling that WuXi AppTec may be preparing to shed its cell and gene therapy business to limit potential exposure to U.S. biosecurity legislation Key Takeaways: The drug…
Recent Articles
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK
603259.SHG
RELATED ARTICLES
-
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK 2359.HK 2268.HK -
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG
-
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK 603259.SHG
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
- CHINA BULLETIN: Manufacturing Déjà Vu
- CHINA BULLETIN: U.S. Ratchets Up Strategic Tariffs
-
WuXi Bio prescribes share buyback to relieve revenue pain
2269.HK
